Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
|
|
- Spencer August Potter
- 5 years ago
- Views:
Transcription
1 Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation /06/ $32.00/0 doi: /j.bbmt High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation William Blum, 1 Brian J. Bolwell, 2 Gary Phillips, 3 Sherif S. Farag, 1 Thomas S. Lin, 1 Belinda R. Avalos, 1 Sam L. Penza, 1 Guido Marcucci, 1 John C. Byrd, 1 Matt E. Kalaycio, 2 Ronald M. Sobecks, 2 Brad Pohlman, 2 Stacey Brown, 2 Patrick J. Elder, 1 Edward A. Copelan 1 1 Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio; 2 Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio Correspondence and reprint requests: William Blum, MD, Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University, B310 Starling-Loving Hall, 320 W. 10th Ave., Columbus, OH ( blum-1@medctr.osu.edu). Received January 12, 2005; accepted June 27, 2005 ABSTRACT Results were analyzed for 48 consecutive patients with acute myeloid leukemia not in remission who underwent unrelated donor bone marrow or stem cell transplantation between 1991 and February 2003 at 2 transplant centers. Forty-six were adults with a median age of 32 years (range, 4-58 years). Forty-two were HLA-A, -B, and -DR matched with their respective donors, and 6 were mismatched at 1 of these loci. The conditioning regimen was myeloablative in all cases: busulfan/cyclophosphamide/etoposide in 34 patients, busulfan/cyclophosphamide in 10 patients, and total body irradiation based in 4 patients. Median follow-up for survivors was 540 days (range, days). Only patients with <5000 peripheral blood blasts per microliter at the time of transplantation survived 2 years (18% versus 0%; P.003). Similarly, patients with <20% blasts in the marrow at the time of transplantation had superior 2-year survival compared with those who had >20% (33% versus 5%; P.04). Patients with <20% blasts who had >3 prior therapies also fared poorly. Cause of death was more commonly treatment related rather than relapse related. This study confirms that patients with acute myeloid leukemia not in remission can achieve prolonged survival with myeloablative conditioning and unrelated donor cell transplantation. However, sustained survival occurs only in patients with a low disease burden at the time of unrelated donor stem cell transplantation, and patients with a high disease burden may benefit from added counseling regarding the high risk of death due to both treatment-related toxicities and disease relapse American Society for Blood and Marrow Transplantation KEY WORDS AML Unrelated donor cell transplantation Disease burden INTRODUCTION Allogeneic transplantation of patients with acute myeloid leukemia (AML) not in remission has curative potential but is associated with high rates of relapse and transplant-related mortality [1,2]. Patients with advanced disease fare poorly compared with those in first complete remission (CR) [1-8]. The Société Francaise de Greffe de Moelle (SFGM) reported outcomes of 379 patients with AML (including only 28 with unrelated donors) who underwent allogeneic transplantation [4]. Five-year overall survival (OS) was 11% to 14% for patients with primary refractory disease (n 69), untreated relapse (n 94), or refractory relapse (n 67), compared with 35% for patients in CR. Similarly, The City of Hope reported a 3-year OS of 30% for patients with primary refractory AML (n 68) [9]. Variables that influenced survival outcome were identified by these 2 studies. In the SFGM report [4], age 15 years, achievement of CR before transplantation, female donor, low-grade or no acute 61
2 W. Blum et al. graft-versus-host disease (GVHD), and the presence of chronic GVHD were favorable prognostic factors. T-cell depletion (TCD) was an adverse factor. In the City of Hope study of refractory AML [9], only an unrelated donor and unfavorable cytogenetics were deemed adverse risk factors. Transplantation from unrelated donors (UDT) for patients with AML not in remission has also been investigated by the Seattle group, which showed a 5-year survival of 7% and 19% for patients who underwent transplantation in relapse (n 81) or with primary refractory disease (n 16), respectively [5]. More recently, a German study reported 16% leukemia-free survival (LFS) at 3 years for patients with AML not in remission who underwent UDT (n 63) [8]. Given the poor long-term survival results after transplantation for patients with AML not in remission and the recognition that transplantation from an unrelated donor further negatively affects outcomes compared with transplantation from a matched sibling donor, it is important to identify prognostic factors to aid clinical decision making about the risk of UDT for patients with AML not in remission who are eligible for the procedure. This investigation analyzed the effect of disease burden on survival for patients with AML not in remission who received UDT. METHODS Patient Identification A search of institutional bone marrow (BM)/stem cell transplantation databases of patients who underwent any type of transplantation at the James Cancer Hospital or the Cleveland Clinic Foundation between 1991 and February 2003 identified 48 patients with AML not in remission who underwent unrelated donor BM (n 46) or filgrastim-mobilized peripheral blood (PB) stem cell (n 2) transplantation. All patients had morphologic evidence of AML at the time of transplantation. Pretransplantation clinical data and survival data were available for all patients identified. Disease burden was measured by both PB and marrow blasts. PB measurements to determine disease burden were from the day of admission for transplantation. BM measurements were within a month before transplantation (and after any prior salvage chemotherapy regimen). Data on the use of cytoreductive medications such as hydroxyurea after marrow measurement and before admission for transplantation were not available. This retrospective analysis was approved by the institutional human studies and privacy committees. HLA Typing and GVHD/Infection Prophylaxis Thirty-one patients had high-resolution DNA typing for HLA-DRB1 by polymerase chain reaction/ sequence-specific priming. Of these, HLA-A and -B typing was performed by high-resolution DNA typing (n 3), low- or intermediate-resolution DNA typing (n 15), or serologic typing (n 13). Sixteen patients had intermediate-resolution typing for DRB1 by polymerase chain reaction/sequence-specific oligonucleotide priming. Of these, HLA-A and -B typing was performed by low- or intermediate-resolution DNA typing (n 8) or serologic typing (n 8). One patient had serologic typing for HLA-A, -B, and -DR. HLA-C testing was performed in 38 patients by highresolution DNA typing (n 6), low- or intermediateresolution DNA typing (n 24), or serologic typing (n 8). For 20 patients with TCD of grafts, selective CD8 lymphocyte depletion was performed from the mononuclear fraction of the stem cell product with Dynabeads M-450 CD8 (Dynal, Oslo, Norway); cells and beads were separated with the MaxStep Magnetic Cell Separator (Baxter, Deerfield, IL). Outcomes for patients who had TCD in this study relative to the effectiveness of TCD and effect of CD8 lymphocyte levels on GVHD have been previously reported [10]. GVHD prophylaxis included tacrolimus and methotrexate in 18 patients, cyclosporine and methotrexate in 27 patients, and cyclosporine alone in 3 patients. Infectious prophylaxis included trimethoprim/sulfamethoxazole (or substitute), antiviral prophylaxis, and amphotericin or fluconazole in all patients. Twenty-four patients also received antibacterial prophylaxis with penicillin VK plus ciprofloxacin or ciprofloxacin alone. Nine patients received prophylactic intravenous immune globulin after transplantation. Engraftment/GVHD Grading The date of myeloid engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count 500/ L. The date of platelet engraftment was the first of 3 consecutive days with a platelet count / L with no platelet transfusions within the prior 7 days. Graft failure was defined as the absence of myeloid engraftment by day 28 after transplantation. Acute and chronic GVHD were defined and graded according to previously published criteria [11,12]. Statistical Analysis Univariate analysis was used to assess the effect on survival of each of the following variables: PB blasts 5000/ L, BM blasts 20%, patient age, no PB blasts, level of HLA-A/-B/-DRB1 matching (intermediate/high versus serologic/low), HLA-C mismatching, 3 prior treatment regimens, total nucleated cell (TNC) dose of transplanted cells per kilogram, acute GVHD, chronic GVHD, duration of first CR, TCD, and cytogenetic risk group. Criteria for PB blasts and 62
3 AML and Unrelated Donor Cell Transplantation BM blasts as noted were chosen for clinical relevancy in a heterogeneous population with AML not in remission. A multivariate Cox proportional hazard model was developed for both OS and LFS by using PB blasts 5000/ L, BM blasts 20%, 3 prior treatment regimens, and patient age. For descriptive purposes, we refer to PB blasts 5000/ L or BM blasts 20% as markers of high disease burden; these criteria were selected on the basis of clinical relevance. The goal of this study was to find the true relationship between OS and disease burden based on these parameters. For this purpose, variables were identified that were confounders or effect modifiers. Variables were added to the logistic regression model and assessed as to whether or not they changed the disease burden hazard ratio by more than 15% in either direction, regardless of the variable s statistical significance. Once a group of variables were established that affected the disease burden s hazard ratio, variables were then assessed as effect modifiers with the risk factor. Continuous variables were tested for linearity by using the method of fractional polynomials, although markers of disease burden were dichotomized as noted. The proportional hazard assumption that the hazard of not surviving was constant across time in the final model was also tested. RESULTS Patient Characteristics Forty-eight patients were identified; 46 were adults. Forty-two patients were HLA-A, -B, and -DR matched with their donors, and 6 were mismatched at 1 of these loci. Eight patients were mismatched at HLA-C (of 38 who had HLA-C typing performed). Eight patients had AML evolved from myelodysplastic syndrome. All patients received myeloablative conditioning regimens. Thirty-four patients were treated with busulfan 14 mg/kg, cyclophosphamide 120 mg/ kg, and etoposide 50 mg/kg; 10 were treated with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg; and 4 were treated with total body irradiation based regimens (1200 Gy in 6 fractions). Forty-six patients received BM grafts, and 2 received filgrastim-mobilized PB stem cells. Twenty patients received CD8 lymphocyte-depleted grafts. Patient characteristics are listed in Table 1. All patients had AML not in remission at the time of transplantation; 17 patients were in first relapse, 16 were in or beyond the second relapse, and 14 had primary refractory disease; 1 patient whose disease had transformed from myelodysplastic syndrome was untreated. Karyotypes of 35 patients were available. According to Cancer and Leukemia Group B criteria [13], patients were assigned the following cytogenetic risk groups: favorable risk, n 4; intermediate risk, n 20; and adverse risk, n 11. Nine patients received salvage chemotherapy within 2 months before undergoing transplantation. Engraftment Thirty-seven patients were evaluable for engraftment. The median time to neutrophil engraftment was 20 days (range, 9-60 days). Primary graft failure occurred in 1 patient. Seven patients were not evaluable for engraftment because they died before day 28 (infection, n 5; hepatic veno-occlusive disease, n 2). Three patients were not evaluable for engraftment because no data were available; these 3 patients died on day 30, day 32, or day 53 as a result of venoocclusive disease, acute respiratory distress syndrome, or infection, respectively. The median time to platelet engraftment was 32 days (range, days; n 22). Acute and Chronic GVHD Acute GVHD occurred in 58% of patients (23 of 40 patients). The incidence of grade I/II GVHD was 35%, and the incidence of grade III/IV GVHD was 20%. Of 25 patients who survived at least 100 days, chronic GVHD data were available for 22 patients. Limited or extensive chronic GVHD occurred in 64% of patients (14 of 22 patients). Causes of Death Treatment-related mortality was the primary cause of death, occurring in 26 (54%) of 48 patients, with 1 case of graft failure. Death due to relapse occurred in 15 (31%) of 48 patients. For 28 patients who received unmanipulated grafts, causes of death were relapse (n 7), GVHD (n 4), infection (n 9), organ toxicity (n 3), and hemorrhage (n 1). For 20 patients who received CD8 lymphocyte-depleted grafts, causes of death were relapse (n 8), GVHD (n 2), infection (n 2), organ toxicity (n 4), and graft failure (n 1). Survival Analysis Figure 1 shows the Kaplan-Meier survival curves for OS based on PB blasts 5000/ L, BM blasts 20%, the presence of any circulating blasts, and the number of prior treatments. Kaplan-Meier survival curves were tested for equality by using a log-rank test. OS for patients with PB blasts 5000/ L was superior to OS in those with higher counts (P.0034). OS for patients with BM blasts 20% was superior to OS in those with higher marrow blasts (P.0356). OS for patients with 3 prior treatments was superior to OS in more heavily pretreated patients (P.0027). OS based on the presence or absence of circulating blasts was not significantly different (P.23). LFS was significantly different between the groups based on PB blasts 5000/ L or BM blasts 63
4 W. Blum et al. Table 1. Characteristics of Patients With AML Not in Remission Who Received UDT Patient No. Age (y) Duration of First CR No. Prior Regimens Disease Status at Transplantation PB Blasts >5000/ L? BM Blasts >20%? TNC of Transplanted Cells ( 10 8 /kg) Overall Survival (d) Alive? Cause of Death REL2 No No Y REL1 No No Y REL2 No No Y 5433* REL2 No Yes Y 4057* 20 2 P-REF No No N GVHD 5119* 31 1 P-REF No Yes N Relapse 5609* REL1 No No Y REL2 No Yes Y REL2 No Yes N Relapse P-REF No No Y 5741* REL1 No No N GVHD 5101* 28 0 Untreated No Yes N Relapse REL2 No Yes N Relapse REL1 No Yes N Bleeding 4062* 37 3 REL1 No No N GVHD REL2 No No N GVHD REL1 No No N Relapse 2253* REL1 No Yes N Relapse 5861* 50 2 P-REFC No No N Relapse REL2 No N Relapse P-REFC Yes Yes N Relapse 5302* P-REFC No Yes N Organ toxicity REL1 No Yes N GVHD P-REF No Yes N Organ toxicity REL1 No Yes N Infection 1788* 19 NA REL1 No Yes N Relapse REL2 No No N Infection REL1 No Yes N GVHD P-REF No No N Infection 5681* REL3 No Yes N Relapse P-REF No Yes N Relapse 5684* REL3 Yes Yes N Relapse 3059* 26 3 REL1 No Yes N Infection 5545* 34 3 REL2 Yes No N Organ toxicity REL2 No No N Infection 5212* REL2 No Yes N Relapse REL2 No No N Relapse REL1 No No N Organ toxicity NA REL1 Yes Yes N Organ toxicity 5807* P-REFC No No N Graft failure P-REFC No Yes N Infection 5874* REL2 No Yes N Organ toxicity REL1 No Yes N Infection P-REF Yes Yes N Infection 2175* 25 NA P-REF No Yes N Organ toxicity 5107* REL1 No Yes N Infection REL No Yes NA 14 N Infection P-REF Yes Yes N Infection CR indicates complete remission; NA, not available; REL, relapsed AML; P-REF, primary refractory AML; P-REFC, primary refractory AML but subsequent remission and then relapse; TNC, total nucleated cell dose. *T cell depleted transplantation. 20% (P.0013 and P.0448, respectively; figure not shown). In the subset of patients (n 21) who had intermediate- or high-level HLA typing for HLA-A/ -B/-DRB1, PB blasts 5000/ L remained a predictor of OS outcomes (P.0232), but BM blasts 20% did not influence outcome (P.5771). Univariate analyses of the other independent variables, including the TNC dose of transplanted cells per kilogram, mismatching at 1 HLA-A/-B/-DRB1 locus, mismatching at HLA-C, acute GVHD, chronic GVHD, duration of first CR, CD8 TCD, and cytogenetic risk demonstrated that none statistically affected survival. Multivariable Cox proportional hazard models were developed for both OS (Table 2) and LFS (Table 3) and consisted of 4 variables: PB blasts 5000/ L, BM blasts 20%, 3 prior treatment regimens, and age. The continuous variable (age) was linear in the 64
5 AML and Unrelated Donor Cell Transplantation Figure 1. Overall survival was dichotomized in 4 different ways. A, Dichotomization is based on a cutoff of circulating blasts 5000/ L. B, Dichotomization is based on 20% bone marrow blasts. C, Dichotomization is based on whether the subject had any circulating blasts. D, Dichotomization is based on whether the patient had 2 prior treatments. All 4 Kaplan-Meier survival curves were tested for equality by using a log-rank test. The P values are shown on each graph. log hazard with fractional polynomials. The models met the proportional hazard assumption. For OS, the hazard ratio for PB blasts showed that the hazard of death was 2.89 times higher for PB blasts 5000/ L as compared with PB blasts 5000/ L (P.053; 95% confidence interval [CI], ). The hazard of death based on BM blasts was affected by the number of prior treatments. For patients with BM blasts 20% and 3 prior treatments, the hazard ratio was 7.31 for patients compared with those who had 20% blasts and 3 treatments (P.001; 95% CI, ). For patients with BM blasts 20%, there was no difference in the hazard of death according to prior treatments. Among patients who received 3 prior treatments, the hazard ratio was 3.91 for patients with BM blasts 20% compared with those with BM blasts 20% (P.014; 95% CI, ). No differences in survival based on PB or BM blasts were detected among patients who received 3 prior treatments (P.629). For LFS, the hazard ratio was 3.51 for PB blasts 5000/ L (P.024; 95% CI, ). For patients with BM blasts 20% and 3 prior treatments, the hazard ratio was 6.92 compared with those with BM blasts 20% and 3 treatments (P.001; 95% CI, ). Among patients who received 3 prior treatments, the hazard ratio for patients with BM blasts 20% was 3.43 compared with those with BM blasts 20% (P.019; 95% CI, ). DISCUSSION The concept of adverse outcomes for patients who enter transplantation with residual disease as compared with those who enter transplantation in remission is intuitive and has been reported by others [5,14]. Patients with AML not in remission and no available related donor have limited therapeutic options, including conventional UDT, investigational transplantation trials, additional chemotherapy, or supportive care. Only UDT offers a hope for cure, but this must be balanced against a high risk of transplantrelated mortality, morbidity, and relapse for those who survive the immediate posttransplantation period. This investigation examined whether clinically relevant measures of disease burden at the time of UDT would have prognostic value for predicting which patients within the subset of AML patients not in remission might have even more dismal outcomes. These patients may be encouraged to participate in other therapies, such as clinical trials that use novel methods of conditioning/transplantation or posttrans- Table 2. Cox Proportional Hazard Model for Overall Survival 95% Confidence Interval Predictor Variable n Hazard Ratio Lower Upper P Value Circulating blasts > 5000/ L* Bone marrow blasts <20% Prior Trt (<2) Prior Trt (>3) Bone marrow blasts > 20% Prior Trt (<2) Prior Trt (>3) Prior Trt (<2) BM blasts <20% BM blasts >20% Prior Trt (>3) BM blasts <20% BM blasts >20% Age Trt indicates treatment. *Referent group is circulating blasts 5000/ L (n 42). 65
6 W. Blum et al. Table 3. Cox Proportional Hazard Model for Leukemia-Free Survival 95% Confidence Interval Predictor Variable n Hazard Ratio Lower Upper P Value Circulating blasts >5000/ L* Bone marrow blasts <20% Prior Trt (<2) Prior Trt (>3) Bone marrow blasts >20% Prior Trt (<2) Prior Trt (>3) Prior Trt (<2) BM blasts <20% BM blasts >20% Prior Trt (>3) BM blasts <20% BM blasts >20% Age Trt indicates treatment. *Referent group is circulating blasts 5000/ L (n 42). plantation therapies. This prognostic information may affect a patient s choice to pursue potentially curative but highly toxic UDT. Our results showed that a high disease burden adversely affected OS and LFS for this poor-risk cohort of patients, with the high disease burden based on clinically relevant parameters of PB blasts 5000/ L and BM blasts 20%. The number of prior treatments was also an important predictive factor for survival in patients with lower disease burden. Patients with AML not in remission and their physicians should consider the especially low survival of the patients with a high disease burden in this study when discussing treatment options such as conventional UDT, because investigational transplantation trials may be attractive alternatives. The predictive value of end points such as pretransplantation circulating PB blasts of 5000/ L, BM blasts 20%, and the number of prior treatments was examined in this cohort of 48 patients. No patient with PB blasts 5000/ L survived 1 year. Likewise, patients with BM blasts 20% had poor survival. Both of these variables are indicators of high disease burden. Survival for patients with BM blasts 20% was influenced by the number of prior treatments, and the presence of BM blasts 20% did not seem to be as important when patients with outmoded HLA typing were excluded from the analysis. No other factor (except age) including GVHD, TCD, or karyotype significantly influenced survival in this study. The results from this large cohort of patients with AML not in remission confirm that such patients can achieve long-term LFS with UDT [4,5,9,15,16]. Sierra et al. [5], summarizing the Seattle experience, reported that conventional UDT for patients with AML not in remission had a higher risk of relapse than transplantation in CR. In this subset of patients, it was noted that patients with 30% leukemic blasts in the marrow and no circulating blasts before transplantation had a lower risk of relapse than those with 30% blasts in the marrow, circulating blasts, or both (P.02). Our results were similar to these findings, although they show that a circulating PB blast count 5000/ L may be a more clinically relevant end point than the presence of no circulating blasts, because a blast count 5000/ L was a predictive factor even in the smaller subset of patients who had more sophisticated HLA typing performed. Disease burden has been reported to affect outcomes for AML patients who are treated with reduced-intensity conditioning (RIC) as well. Maris et al. [17] reported inferior survival for patients with 5% marrow blasts at the time of transplantation for a mixed cohort of patients (n 89) treated with RIC and UDT. Sayer et al. [18] reported that AML patients with 20% marrow blasts or 5% to 20% marrow blasts had inferior survival after RIC and allogeneic transplantation compared with patients who had 5% marrow blasts (event-free survival of 14%, 24%, and 49%, respectively; P.001). The dose of transplanted cells has previously been shown to affect outcome in patients undergoing allogeneic transplantation [5,19-21]. For patients with AML not in remission undergoing conventional UDT in 1 study [5], those with a transplanted cell dose above the median ( nucleated cells per kilogram) had a 5-year LFS of 13%, versus 2% for those who received cell doses below the median (P.20). By shortening the time to count recovery and potentially increasing a graft-versus-leukemia effect, it is logical that a higher transplanted cell dose may be especially important for patients with advanced disease, who are at the highest risk for relapse [21]. However, the transplanted cell dose did not significantly affect outcome in the present cohort of patients. Furthermore, TCD, which typically leads to a lower TNC dose, did not adversely affect survival, in contrast to the SFGM study [4], which reported an 66
7 AML and Unrelated Donor Cell Transplantation adverse effect of TCD (and included patients in CR and predominantly sibling transplants). This difference may be due to variation in patients or donors or to the use of selective CD8 TCD in the current study. CD8 TCD, as in this study, has been previously reported to deplete the CD8 lymphocyte dose by 2 logs. A higher CD8 cell dose was associated with more severe acute and chronic GVHD in these patients [10]. This study of 48 patients with AML not in remission who underwent myeloablative UDT demonstrates that consideration of objective measures of disease burden and the number of prior treatments may be helpful in the identification of patients who have an exceedingly low chance of a favorable outcome. For heavily pretreated patients or those with a high disease burden, especially those with PB blasts 5000/ L, counseling regarding the high risk of death from not only relapse, but also, more commonly, from treatment-related complications should be provided. Discussion of alternatives, including investigational transplantation trials or other therapies, would add important information for such patients. REFERENCES 1. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992;80: Mehta J, Powles R, Horton C, et al. Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transplant. 1994;14: Geller RB, Saral R, Piantadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood. 1989; 73: Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26: Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26: Hallemeier C, Girgis M, Blum W, et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cgy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2004;10: Copelan EA, Biggs JC, Thompson JM, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991;78: Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005;35: Fung HC, Stein A, Slovak M, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9: Kalaycio M, Rybicki L, Pohlman B, et al. CD8 T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant. 2005;35: Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18: Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 1978;91: Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100: Girgis M, Hallemeier C, Blum W, et al. Chimerism and clinical outcomes of 110 unrelated donor bone marrow transplant recipients conditioned with low dose (550 cgy), single exposure total body irradiation and cyclophosphamide. Blood. 2004;105: Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol. 1992;10: Godder KT, Mehta J, Chiang KY, et al. Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant. Bone Marrow Transplant. 2001;28: Maris MB, Niederwieser D, Sandmaier BM, et al. HLAmatched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102: Sayer HG, Kroger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31: Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Singhal S. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood. 1997;90: Singhal S, Powles R, Treleaven J, et al. A low CD34 cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should CD34 cells/kg be considered the minimum threshold? Bone Marrow Transplant. 2000;26: Dominietto A, Lamparelli T, Raiola AM, et al. Transplantrelated mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:
KEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationAllogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission Je-Hwan Lee 1, Sung-Soo
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More information& 2007 Nature Publishing Group All rights reserved /07 $
(7), 437 441 & 7 Nature Publishing Group All rights reserved 268-3369/7 $. www.nature.com/bmt ORIGINAL ARTICLE Patients mobilizing large numbers of CD34 þ cells ( super mobilizers ) have improved survival
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationKEY WORDS: Total body irradiation, acute myelogenous leukemia, relapse
The Addition of 400 cgy Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality
More informationDoes anti-thymocyte globulin have a place in busulfan/fludarabine
ORIGINAL ARTICLE Korean J Intern Med 2016;31:750-761 Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Young
More informationMonosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia
Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul Oran, 1 Michelle Dolan, 2 Qing Cao, 1 Claudio Brunstein,
More informationXiao-Jun Huang & Yu Wang & Dai-Hong Liu & Lan-Ping Xu & Huan Chen & Yu-Hong Chen & Wei Han & Hong-Xia Shi & Kai-Yan Liu
J Clin Immunol (2008) 28:390 397 DOI 10.1007/s10875-008-9193-4 Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients
More informationIntensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation
More informationLow-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation
Biology of Blood and Marrow Transplantation 9:453-459 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0005$30.00/0 doi:10.1016/s1083-8791(03)00139-3 Low-Dose Total Body
More informationBMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014
Core Study Participants: Baylor College of Medicine (Methodist ) BMT at Northside Hospital Case Western Reserve University Consortia Cleveland Clinic Foundation Oregon Health and Science University University
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationKT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.
(2001) 28, 1031 1036 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Acute myeloid leukaemia Partially mismatched related donor bone marrow transplantation as salvage
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationOptimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS)
Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) H. Joachim Deeg Myelodysplastic syndrome (MDS) is a hemopoietic stem cell disorder that is potentially curable by transplantation
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More information2/4/14. Disclosure. Learning Objective
Utilizing Intravenous Busulfan Pharmacokinetics for Dosing Busulfan And Fludarabine Conditioning Regimens In Institutions Where The Capability Of Doing Pharmacokinetics Is Not Present Shaily Arora, PharmD
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationExperimental Hematology 31 (2003)
Experimental Hematology 31 (2003) 1182 1186 Busulfan-cyclophosphamide versus total body irradiation cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationClinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes
Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationAllogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )
TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationClinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
More informationThe New England Journal of Medicine BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA
BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA JOHN A. HANSEN, M.D., THEODORE A. GOOLEY, PH.D., PAUL J. MARTIN, M.D., FREDERICK APPELBAUM, M.D., THOMAS R. CHAUNCEY,
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationDonor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma
(2002) 29, 65 620 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation
More informationKEY WORDS Leukemia Myelodysplastic syndrome Transplant Aging
Biology of Blood and Marrow Transplantation 13:454-462 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1304-0001$32.00/0 doi:10.1016/j.bbmt.2006.11.024 Allogeneic Hematopoietic
More informationCorrespondence should be addressed to Yingjun Chang;
Hindawi Immunology Research Volume 2017, Article ID 1043836, 8 pages https://doi.org/10.1155/2017/1043836 Research Article Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated
More informationQi-Fa Liu, 1 Zhi-Ping Fan, 1 Yu Zhang, 1 Zu-Jun Jiang, 2 Chun-Yan Wang, 3 Dan Xu, 1 Jing Sun, 1 Yang Xiao, 2 Huo Tan 3
Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation for Refractory Leukemia Qi-Fa Liu,
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationEffect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationKEY WORDS. Acute lymphoblastic leukemia Etoposide Cyclophosphamide Total body irradiation Conditioning regimen Sibling allografts
Biology of Blood and Marrow Transplantation 12:438-453 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1204-0007$32.00/0 doi:10.1016/j.bbmt.2005.12.029 A Comparison of Cyclophosphamide
More informationComparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:1326-1334 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1212-0001$32.00/0 doi:10.1016/j.bbmt.2006.08.035 Comparison of Reduced-Intensity
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationMyelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers
(23) 32, 35 4 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers A Daly 1,
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More informationSTEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationReduced-Intensity Allogeneic Bone Marrow Transplantation
Reduced-Intensity Allogeneic Bone Marrow Transplantation Session Chair: Claudio Anasetti, MD Speakers: Brenda M. Sandmaier, MD; Issa F. Khouri, MD; and Franco Locatelli, MD Outcomes with Myeloid Malignancies
More informationCHAPTER 2 PROTOCOL DESIGN
CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationEffect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, 1,2 John E. Wagner, 1,3 Todd E. DeFor, 1 Daniel J. Weisdorf, 1,2 Claudio
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationBiol Blood Marrow Transplant 17: (2011) Ó 2011 American Society for Blood and Marrow Transplantation
Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationClinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:965-972 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1209-0001$32.00/0 doi:10.1016/j.bbmt.2006.05.018 Clinical Outcome following
More informationISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin
More informationAllogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Policy Number: 8.01.21 Last Review: 1/2019 Origination: 12/2001 Next Review: 1/2020 Policy Blue
More informationExperience of patients transplanted with naïve T cell depleted stem cell graft in CMUH
Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationHematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia
398 Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Qifa Uu Zhiping Fan Jing Sun Yu Zhang Xiaoli Uu Dan Xu Bing Xu Ru Feng Fanyi Meng Shuyun Zhou Department of Hematology,
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More information